Your source for all Prime Therapeutics' May 2026 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for May 2026 will keep you informed on what’s trending now and trending clinical topics. 

---

Released May 5, 2026

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are brepocitinib/Riovant, rebisufligene etisparvovec/Ultragenyx and more.

---

Released May 12, 2026

FDA Decisions Expected: June 2026

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers ensitrelvir, tebipenem HBr and more.

---

Released May 22, 2026

GLP-1 Pipeline Update

A quartely view of the GLP-1 pipeline and anticipated indications, offering a credible clinical snapshot of what's ahead. See what's coming in the emerging GLP-1 landscape.

---

Released May 26, 2026

Oncology Insights

Featuring commentary by Abby Kim, PharmD, BCOP, on developments in the oncology space, this installment reviews advancements in treating pancreatic cancer, often one of the most difficult types of cancer to treat. 

---

Released May 31, 2026

Trending Topics & Drug Approvals: May 2026

Prime covers hot topics and the latest specialty and traditional drug approvals. The latest edition covers the FDA's proposal to withdraw avacopan oral capsule (Tavneos) from commercilization in the United States, citing recent evidence that Tavneos hasn't demonstrated efficacy for its approved indication.

---

Looking for previous 2026 drug insights publications?

Simply click on the month to access past editions of our drug insights.

January 2026
February 2026
March 2026
April 2026